vimarsana.com
Home
Live Updates
Key Trial Updates Confirm and Clarify Treatment Approaches Across Genitourinary Cancers : comparemela.com
Key Trial Updates Confirm and Clarify Treatment Approaches Across Genitourinary Cancers
Matthew Galsky, MD, highlights updates in metastatic urothelial cancer treatment, as well as the evolution of PARP inhibitors and the optimal use of intensified triplet therapy in prostate cancer.
Related Keywords
New York ,
United States ,
Columbia University ,
Scottt Tagawa ,
Markn Stein ,
Che Kai Tsao ,
Genentech Roche ,
Glaxosmithkline Incyte ,
Bristol Myerssquibb ,
Scot Niglio ,
Matthew Galsky ,
Astellas Pharma ,
Columbia University Medical Center ,
Genentech ,
Serono ,
Novartis ,
Icahn School Of Medicine At Mount Sinai ,
Bristol Myers Squibb ,
National Cancer Institute Clinical Trials Network ,
Infinity Pharmaceuticals ,
Pfizer ,
Gilead Sciences ,
Alliance For Clinical Trials In Oncology ,
Icahn School Of Medicine ,
Astrazeneca ,
Langone Health ,
Inovio Pharmaceuticals ,
Tisch Cancer Institute ,
Science Summit ,
Bladder Cancer ,
Mount Sinai ,
New York City ,
New England Journal ,
Weill Cornell Medicine ,
Icahn School ,
Clinical Trials ,
Aileron Therapeutics ,
Dragonfly Therapeutics ,
Seattle Genetics ,
Silverback Therapeutics ,
Janssen Oncology ,
The Tisch Cancer Institute At Mount Sinai ,
News ,
Genitourinary Cancers ,
comparemela.com © 2020. All Rights Reserved.